En Es
Categories

Industry News

DiaSorin to Acquire Siemens' ELISA Immunodiagnostics Business

By Labmedica International staff writers
01 Aug 2017

Image: DiaSorin has entered into an agreement to acquire Siemens Healthineers’ micro-titre-based ELISA immunodiagnostic business portfolio (Photo courtesy of iStock).DiaSorin S.p.A. (Saluggia, Italy) has entered into an agreement to acquire Siemens Healthineers’ (Erlangen, Germany) micro-titre-based ELISA immunodiagnostic business portfolio and related tangible and intangible assets, including customer sales and distribution contracts, installed base of instruments and relevant intellectual property.

DiaSorin develops, produces and markets reagent kits for IVD worldwide, and offers a broad range of specialty tests in the immunodiagnostics market and new tests in the molecular diagnostics markets. Siemens Healthineers offers a comprehensive portfolio of products and services in its core areas of diagnostic and therapeutic imaging and in laboratory diagnostics and molecular medicine. The company’s ELISA immunodiagnostic products are marketed in hospitals, private laboratories and blood banks.

DiaSorin will acquire the ELISA immunodiagnostic business portfolio and relevant assets from Siemens Healthineers, excluding the transfer of employees or manufacturing facility and capability, on a debt-free cash-free basis for a total consideration of up to Euro 47.5 million.

Siemens Healthineers will continue to manufacture and provide its ELISA immunodiagnostic reagent kits exclusively to DiaSorin for up to three years, enabling continuous supply of its current ELISA immunodiagnostic products to customers.

The acquisition is in line with DiaSorin’s strategy to convert customers using ELISA products to its CLIA platforms and products solution, leveraging on the completeness of its CLIA menu and the features of its LIAISON platforms. Siemens Healthineers’ ELISA immunodiagnostic business portfolio will allow DiaSorin to access a significant customer base, mostly in Europe, thus providing it with the opportunity to further expand its global commercial presence to create new business opportunities for the promotion and marketing of its CLIA products.

“We are very excited to acquire the Siemens Healthineers ELISA business,” said Carlo Rosa, CEO of DiaSorin Group. “We think this deal would perfectly fit with our long-term strategy aimed at expanding our customer base leveraging on our extensive CLIA specialties menu and LIAISON Platforms.”



E-mail Print
FaceBook Twitter Google+ Linked in

DIASORIN

DiaSorin develops, produces and commercializes diagnostic tests for a wide range of clinical areas. The company’s tests are designed for hospital and private testing laboratories in the markets of immunodiagnostics and molecular diagnostics.
More info

Additional news

18 Jan 2022
Global Coagulation Analyzers Market Driven by Growing Awareness About Timely Diagnosis of Blood Clots
The global coagulation analyzers market is expected to reach USD 11.7 billion by 2028, driven by the increasing understanding of blood clots and the fact that they can be avoided with early detection.
Read More
17 Jan 2022
Mobile C-Arms Market to Surpass USD 1.6 Billion in 2027 Due to Growing Preference for Minimally Invasive Surgeries
The global mobile C-arms market is expected to grow at a CAGR of 5.2% from USD 1.07 billion in 2019 to USD 1.61 billion in 2027, driven primarily by an increase in the global geriatric population, rising burden of chronic and acute diseases across the world, increasing volumes of orthopedic, cardiac, neurological, and oncological surgical procedures, and growing preference for minimally invasive surgeries.
Read More
14 Jan 2022
Medlab Middle East to Reveal Latest Innovations and Technologies in Mobile Labs for COVID-19 Testing
The latest technology and innovation in the global fight against COVID-19 and beyond will be on show at the next edition of Medlab Middle East when it returns to the Dubai World Trade Center from 24-27 January 2022 with mobile molecular testing and diagnosis stations, or ‘laboratories on wheels’, from companies such as Seegene, Inc. (Seoul, Korea) taking center stage.
Read More
13 Jan 2022
Global Coagulometers Market to Be Driven by Rising Prevalence of Blood Disorders
The global coagulometers market is being driven by a rise in the incidence and prevalence of blood disorders such as hemophilia that is fueling the demand for more diagnostic tools.
Read More
11 Jan 2022
Medlab Middle East to Return as Standalone Event in 2023
Informa Markets (London, UK), organizers of Medlab Middle East, have announced that the MENA region’s leading exhibition for the laboratory industry will return to a standalone event in 2023.
Read More
11 Jan 2022
J&J Medical Devices Companies Partners with Microsoft to Further Enable its Digital Surgery Solutions
The Johnson & Johnson Medical Devices Companies (JJMDC; New Brunswick, NJ, USA) will collaborate with Microsoft (Redmond, Wash., USA; www.microsoft.com) to further enable and expand JJMDC’s secure and compliant digital surgery ecosystem.
Read More
10 Jan 2022
ICU Medical Completes Acquisition of Smiths Medical to Create Leading Infusion Therapy Company
ICU Medical Inc. (San Clemente, CA, USA) has completed its acquisition of Smiths Medical (Minneapolis, MN, USA) from Smiths Group plc that includes syringe and ambulatory infusion devices, vascular access, and vital care products. When combined with ICU Medical's existing businesses, the combined companies create a leading infusion therapy company.
Read More
05 Jan 2022
Global Portable Ultrasound Scanner Market to Be Driven by Rising Trauma and Accident Cases
The global portable ultrasound scanner market is being driven by an increase in targeted illnesses, rise in trauma & accident cases, surge in demand for less invasive operations, and the emergence of a senior population at a high risk of diseases.
Read More
04 Jan 2022
Global Mammography Workstations Market to Surpass USD 0.19 Billion in 2028 Due to Increasing Prevalence of Breast Cancer
The global mammography workstations market is projected to grow at a CAGR of 6.8% from about USD 0.12 billion in 2020 to more than USD 0.19 billion in 2028, led by increasing prevalence of breast cancer across the world, growing need for early breast cancer diagnosis and treatment, rise in government initiatives to spread breast cancer awareness, and rapid adoption of advanced mammography workstations in hospitals, clinics, and breast care centers.
Read More
Copyright © 2000-2022 TradeMed.com. All rights reserved. | Terms And Conditions